CTOs on the Move


 
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer. The company is located in Menlo Park, California. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.grail.com
  • 1525 O`Brien Drive
    Menlo Park, CA USA 94025
  • Phone: 650.542.0372

Executives

Name Title Contact Details
Janet G.
Head of Security Profile
Satnam Alag
Senior Vice President of Software Engineering Profile
Angela Lai
Chief Technology Officer Profile

Funding

Grail raised $125M on 12/16/2019
Grail raised $390M on 05/06/2020

Similar Companies

Syngenta Biotechnology Inc

Syngenta Biotechnology Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Iovance Biotherapeutics

Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California.

Cellartis AB

Cellartis AB is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Insitro

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We`re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes.

Lumos Diagnostics

Lumos Diagnostics delivers custom diagnostic solutions by combining deep market insight with existing platform technologies, assay development capability and regulated manufacturing experience.